Companies Related to "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" [Most Relevant Company Matches] - Page: 20 RSS

22:22 EDT 25th March 2019 | BioPortfolio

Here are the most relevant search results for "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Gemcitabine Carboplatin With Without PARP1 Inhibitor Patients" Companies 476–500 of 4,400+

Probably Relevant

Veristat, LLC.

Bringing 20 years of experience to its clients, Veristat is a clinical research organization (CRO) that supports pharmaceutical, biotechnology and medical device companies through every phase of the clinical trial process, as well as the preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Visit ...

XCPT Communication Technologies, LLC

XCPT(TM) Treatment Planning and Communication Software was developed to provide an innovative communication method for patients and their healthcare professionals. With its adoption, communication becomes clearer for dental teams in their relationships with patients, their team members, and their referral networks.

MILLENNIX, A Division of IT & E International Group, Inc.

MILLENNIX, A Division of IT & E International Group, Inc. is a full service Clinical Research Organization providing a broad spectrum of clinical research services that include "Best in Class" solutions to your clinical trial needs including compliance and validation of all clinical, laboratory, manufacturing and IT systems.IT&E International Regulatory Compliance Group provides compliance, valida...

Spry Health

Spry Health, incubated at Stanford-affiliated accelerator StartX, delivers on the promise of wearables to transform how chronically ill patients are treated, improve patient outcomes, and dramatically reduce healthcare costs. Founded in 2014 with a vision to transform health solutions, the company creates a new channel of information from the most vulnerab...

Neurogene, Inc.

Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring therapies to patients that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatmen...


VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. QNEXA is also in phase 2 clinical development for the tr...


Aster.cephac is a full service provider of Clinical Pharmacology trials and Bioanalytical Service.Since 1975 We have served the pharmaceutical and biotechnology industries with expertise and innvotion as as Early Phase clinical trial specialist,and have become the largest independent bioanalytical unit in Europe

ClinicalTrialsNet Inc

ClinicalTrialsNet has developed a clinical trials software system that allows research personnel to easily conduct their activities in full compliance with HIPAA and FDA regulatory guidelines. Project and data management for both paper-based and web-based studies are combined in one online environment to facilitate fully centralized research management. This benefits not only researchers but also ...

DMC Medical Group

DMC Medical Group is an extension of the DMC physician family, caring for patients in locations all over town – and backed by all the resources of Detroit Medical Center. The DMC Medical Group is committed to providing patients with a more modern, streamlined healthcare experience, where accessibility and convenience are key.

Kepivance™ (palifermin)

Kepivance™ (palifermin) is indicated to decrease the incidence and duration of severe oral mucositis (mouth sores) in patients withhematologic (blood) cancers undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplant. The safety and efficacy of Kepivance™ have not been established in patients with nonhematologic malignancies.

VenatoRx Pharmaceuticals, Inc.

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel agents to address the threat of antibiotic bacteria resistance. Its lead clinical program combines VNRX-5133, a novel β-lactamase inhibitor, with an approved and marketed β-lactam antibiotic. This press release contains “forward-looking ...


Genzyme is one of the world’s leading biotechnology companies. Its more than 9,000 employees work in countries throughout the world and are united by a common goal: to make a major positive impact on the lives of people with debilitating diseases. Since its founding in 1981, Genzyme has grown from a small start-up to a diversified enterprise with 2006 revenues of $3.2 billion. Over the past two...

Kibow Biotech Inc

Kibow Biotech Inc. was founded in 1997 by Dr. N. Ranganathan and Dr. Jack Dickstein. Kibow Biotech Inc. started out to fill the void in treatments for patients with chronic kidney disease. Since then Kibow Biotech Inc. has been actively researching on ways and methods to develop a cost-effective non-invasive treatment for kidney disease patients. This has since became our mission statement. The co...


SCIREX Corporation is a leader in the delivery of Phase I-IV drug development services to the global pharmaceutical and biotechnology industries. Our Services and Capabilities include:Clinical Trial Management Project teams with excellent experience, expertise and capabilities specific to your project


R-Health's innovative Direct Primary Care model is designed to deliver better healthcare at a lower cost. R-Health Direct Primary Care liberates primary care from the administrative cost burden and negative incentives of the current fee-for-service insurance system. Physicians can deliver personalized, effective, coordinated, patient-centered care that is ...

Thuris Corporation

Thuris is focused on the development of pharmaceuticals for select niche indications, including: a stroke-related condition, peripheral neuropathy, and Huntington's disease. The Company also has received FDA clearance for a 510(k) medical device, the NeuroGraphTM, designed to aide in diagnosis, clinical trial enrollment, and endpoint monitoring for Central Nervous System (CNS) disorders.

Rx Canada

Rx Canada's goal is to create collaboration between pharmacists, physicians and patients by providing quality adherence programs and services that ultimately help patients better understand and manage their health and medications. Since established in 1997, Rx Canada has focused on the development of effective, standardized pharmacy based adherence programs. Rx Canada's programs provide patients w...


Medumo improves care delivery by delivering a content platform to automatically guide patients throughout their care journey. The patient navigation platform enables patients to be appropriately scheduled, reduce late cancellations and no shows as well as have all their pre-appointment tasks completed and continue to follow instructions when they go home ...

CompleWare Corporation

CompleWare Corporation provides sponsors with state-of-the-art services, software and support to collect and manage clinical trial data. CompleWare isa leader in the capture and management of case report form, patient reported outcome (diary) and physiological data using innovative electronic processes.

Cook Group Inc.

Cook Group is headquartered in Bloomington, Indiana, having been established by Bill and Gayle Cook over 50 years ago. Cook Group employs over 11,000 people worldwide at a range of companies focusing on medical devices, cellular and biologic tissue products, clinical trial management, and contract manufacturing.

Personalized Pharmaceutical Systems

Personalized Pharmaceutical Systems (PPS) is a cutting edge clinical trial enhancement and market differentiation company designed to dramatically reduce risk for pharmaceutical companies in both drug development and post-market entry phases. PPS novel enrichment technology utilizes inter-individual variability, that currently confounds drug trials, to enhance efficacy outcomes and/or significantl...

Pennsylvania Hand Center

The Pennsylvania Hand Center is a tertiary care center for problems of the hand, wrist and upper extremity. Our referrals from other physicians and past patients attest to the expertise of our services. Our patients know that we can make them better or, at the very least, no-one can try harder to help them. We are able to do this through our continuous education programs and constant efforts to re...

Zynex Medical

Since 1996, Zynex Medical has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex Medical continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and...

Respiratory Motion, Inc.

ExSpiron continuously and noninvasively measures and displays lung volume against time, generating quantitative metrics for minute ventilation (the amount of air that enters/leaves the lungs every minute), respiratory rate (breaths per minute), and tidal volume (the volume of air in a single breath). Minute ventilation was previously only captured continuo...


Recruitment. Retention. Results.   MediciGlobal® is a specialty patient recruitment-retention firm serving the clinical trials industry. Liz Moench’s founding vision in 1991 was to create a company that addressed the primary cause of clinical trial delays: ineffective patient recruitment. An industry pioneer, Liz Moench introduced the first direct-to-consumer advertising pro...

More From BioPortfolio on "Trial of Gemcitabine/Carboplatin With or Without BSI-201 (a PARP1 Inhibitor) in Patients With Previously Untreated Advanced Squamous Cell Lung Cancer"

Quick Search


Corporate Database Quicklinks